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Background: Mycobacterium tuberculosis encodes 11 putative serine-threonine proteins Kinases (STPK) which
regulates transcription, cell development and interaction with the host cells. From the 11 STPKs three kinases
namely PknA, PknB and PknG have been related to the mycobacterial growth. From previous studies it has been
observed that PknB is essential for mycobacterial growth and expressed during log phase of the growth and
phosphorylates substrates involved in peptidoglycan biosynthesis. In recent years many high affinity inhibitors are
reported for PknB. Previously implementation of data fusion has shown effective enrichment of active compounds
in both structure and ligand based approaches .In this study we have used three types of data fusion ranking
algorithms on the PknB dataset namely, sum rank, sum score and reciprocal rank. We have identified reciprocal rank
algorithm is capable enough to select compounds earlier in a virtual screening process. We have also screened the
Asinex database with reciprocal rank algorithm to identify possible inhibitors for PknB.
Results: In our work we have used both structure-based and ligand-based approaches for virtual screening, and
have combined their results using a variety of data fusion methods. We found that data fusion increases the chance
of actives being ranked highly. Specifically, we found that the ranking of Pharmacophore search, ROCS and Glide
XP fused with a reciprocal ranking algorithm not only outperforms structure and ligand based approaches but also
capable of ranking actives better than the other two data fusion methods using the BEDROC, robust initial
enhancement (RIE) and AUC metrics. These fused results were used to identify 45 candidate compounds for further
experimental validation.
Conclusion: We show that very different structure and ligand based methods for predicting drug-target
interactions can be combined effectively using data fusion, outperforming any single method in ranking of actives.
Such fused results show promise for a coherent selection of candidates for biological screening.
Keywords: PknB, Virtual screening, Data fusion, BEDROC, Reciprocal rankBackground
Most people affected by tuberculosis contain both active
infection and latent infection. The mechanism of
Mycobacterium tuberculosis shift between the latent and
active state is not clearly understood, but one of the essen-
tial components of these kind of systems is the regulation
of cell wall synthesis and cell division in response to sti-
muli from the host via signal transduction. One of the chief
mechanisms by which extracellular signals are translated to
intracellular responses is via protein phosphorylation. In* Correspondence: pyogee@bits-hyderabad.ac.in
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reproduction in any medium, provided the orbacteria Protein phosphorylation is carried out by specific
protein kinases in a two component system. In eukaryotes
protein phosphatases and protein kinases plays a key role
behind of host and pathogen signal transduction path-
ways. Mycobacterium tuberculosis having 11 serine-
threonine proteins Kinases (STPKs) and it has been found
that Ser/Thr kinases are an attractive target for drug
discovery [1,2]. The 3D structures of PknB, PknE and
PknG are required for mycobacterial growth [3] and are
being deposited in PDB (www.rcsb.org) which resemble
the human kinases with conserved motif and a striking
similarity of ATP bound kinase domain with the activated
eukaryotic Ser/thr Kinases [4]. PknB is a receptor like pro-
tein transmembrane protein with an extracellular signal
sensor domain (PASTA) and an intracellular kinaseLtd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Seal et al. Journal of Cheminformatics 2013, 5:2 Page 2 of 11
http://www.jcheminf.com/content/5/1/2domain and it shares high sequence similarity with
eukaryotic STPKs [4,5]. PknB is a very important func-
tional protein kinase which can phosphorylate by itself. It
has been shown that the expression of PknB is constitutive
and is present under both in vitro and in vivo conditions.
Previously MtrA was response regulator for Mycobacter-
ium tuberculosis and found to be essential for growth [5].
Further it was also observed Fernandez [6] that knock-
outs and overexpression of PknB affects the cell mor-
phology which supports involvement of with cell division
and shape which shows that PknB is the right molecular
target for designing inhibitors. There is a need for the de-
sign of new inhibitors because current drugs, whilst effect-
ive in vitro have not shown good in vivo activity. Our
hypothesis is that this is because the compounds are not
targeting PknB in cells. Though the sequence identity is
less than 27% and the PknB structure shows a very low
RMSD of 1.36 Å and 1.72 Å with eukaryotic kinases [7-9],
the overall catalytic domain is similar to the eukaryotic
protein kinase consisting the N terminal subdomain in-
cluding a β-sheet and a long α-helix and the C terminal
lobe consists of α-helices [10]. In this work we have
used ligand and structure based approaches to screen large
set of inhibitors. Previously many high affinity inhibitors
have been reported for PknB [11-15]: we used 62 inhibi-
tors listed in Additional file 1 for our work.
Virtual screening (VS) using structure and ligand based
approaches is widely used in drug discovery [16].
Structure-based screening involves using information
about a protein target, usually through molecular docking.
It requires a protein structure to be known, but known ac-
tive ligands are not required. Ligand-based screening only
uses information from active ligands, but does not require
a protein target structure. Both structure and ligand based
approaches can be applied parallel to VS, but often these
approaches are applied in a stepwise filtering approach
[17]. The most commonly applied VS methods are mo-
lecular docking, pharmacophore identification and ligand
similarity (including shape based), along with a variety of
machine learning methods that “learn” to differentiate
actives from inactives based on known data [18,19]. Simple
similarity searching with known ligands can also be effect-
ive [20,21].
The most important challenge in VS is to create accurate
scoring function that can distinguish between novel bio-
active and inactive molecule. In case of docking the three
classes of scoring is highlighted forcefield based scoring,
empirical scoring and knowledge based scoring [22]. The
three classes include various types of scoring algorithms
are used for molecular docking, historically, scoring does
not correlate well with binding activity, although Consen-
sus scoring, which takes a weighted average of several
methods, can result in improvements [23,24]. However,
these consensus scores are only concerned with variationsof a structure-based approach and their limitations have
been documented [25]. Data Fusion has been shown to be
effective in integrating data from different sources [26-28]
for example Willet etal used 2D similarity searching using
different similarity measures using SUM function, al-
though there are few results reported using structure and
ligand based approaches along with data fusion [29,30].
In this study we have applied multiple ligand and struc-
ture based methods to the PknB problem and then com-
bined these results using data fusion. Performance was
evaluated with a widely used benchmark dataset from
Schrodinger (http://www.schrodinger.com/glidedecoyset),
which has been used in other VS [31,32]. This set is a set
of decoys that have similar properties to the active com-
pounds but are topologically dissimilar. We also evaluated
ranking of actives using a variety of well-established me-
thods including Enrichment factor (EF) [31], RIE [33] and
BEDROC [34,35]. We used the EF,RIE and BEDROC in
the each of the VS protocols and in the data fusion algo-
rithms such as sum score, sum rank and reciprocal rank
and found that reciprocal rank outperformed all of the VS
protocols such as pharmacophore search, shape screening
and docking and as well as related to other algorithms.
The next best algorithm which performed well in data fu-
sion was sum score rank which outperformed the struc-
ture and ligand based approaches.
The aim of the study was to utilize several VS proto-
cols and then fuse the results for evaluation the results
and identify best fusion algorithm among the 3D struc-
ture based, ligand based methods and fusion algorithms,
and to show how these results could be used to select
compounds for follow-up testing.
Methods
Dataset preparation
For PknB many inhibitors were earlier reported like amino-
pyrimidine analogues and aminopyrazoles [11-15]. The
reported lists of 62 inhibitors were drawn in chemaxon’s
Marvin sketch application [36]. Some of structures of active
compounds are given in Figure 1. The decoy set of molecu-
lar weight 400Da was downloaded from the Schrodinger’s
website. For screening freely available molecular database
of Asinex was used in the study which consisted of 3,
93,000 molecules. All the structures were prepared using
LigPrep (LigPrep v2.2, Schrodinger LLC, New York, NY)
with Epik (Epik v1.6, Schrodinger, LLC, New York, NY) to
expand protonation and tautomeric states at 7.0 ± 2.0 pH
units.
Conformational sampling was performed on all data-
base molecules using the ConfGen search algorithm
[37]. Confgen with OPLS 2005 forcefield was applied
for generation of conformers with duplicate poses eli-
minate if the RMSD is less than 1.0 Å. A distance
dependent dielectric constant of 4 and maximum
Figure 1 Some of the PknB inhibitors stsructures with IC50 values.
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suggested by salam etal [38]. For validation of the struc-
ture and ligand based approaches we used a randomly
selected set of 35 active compounds from the dataset of
62 active compounds and 1000 decoy compounds ma-
king a total of 1035 compounds as the database given in
Additional file 2.Protein preparation
For protein preparation PknB inhibitor Mitoxantrone
(Mtz) bound crystal structure PDBID: 2FUM was pre-
pared using the protein preparation wizard. Bond orders
and formal charges were added for hetero groups, and
hydrogens were added to all atoms in the system. Water
molecules were removed. A brief relaxation was per-
formed using an all-atom constrained minimization car-
ried out with the Impact Refinement module (Impref)
(Impact v5.0, Schrodinger, LLC, New York, NY) using the
OPLS-2005 force field to alleviate steric clashes that may
exist in the original PDB structures. The minimization was
terminated when the energy converged or the rmsd
reached a maximum cutoff of 0.30 Å.Virtual screening methods
Three methods of VS were applied in the current study:
Docking using Glide [32,37], e-pharmacophore search
using phase [39] and 3D shape similarity search using
vROCS [40]. Our aim was to investigate whether data fu-
sion methods can search and rank actives from a database.
For docking, the extra precision (XP) mode was used
both for the actives and decoy sets and all settings were
left as default except for adding the Epik states penalties
to the docking score. Glide energy grid was generated
using 2FUM structure. It was found that the glide grid
for the ligand was smaller using the default settings so itwas extended to 12Å to cover all the ligands and the ac-
tive site grid covered whole of the active site.
To generate the pharmacophoric features we used the
energetic pharmacophore as developed by Salam et al. It is
a very useful method unlike ligand based pharmacophore
which requires a set of structures and also skill in defining
proper training and test sets. The e-pharmacophore can
be developed with a single active compound. The 62 active
compounds were docked into the crystalline ligand struc-
ture using the Glide XP refine docking algorithm. The
Glide XP descriptors generated were used in building the
e-pharmacophore from the Maestro Scripts menu option
with default excluded volume option 0.5 pharmacophoric
sites were automatically generated with Phase using the
default set of six chemical features: hydrogen bond ac-
ceptor (A), hydrogen bond donor (D), hydrophobic (H),
negative ionizable (N), positive ionizable (P), and aromatic
ring (R). We generated 4 different e-pharmacophores for
2FUM given as Figure 2 and from that we have evaluated
the best one using the statistical metrics discussed in
results and discussion section. Phase findmatches was used
to generate conformers of the compounds on the fly on
screening the active and decoy sets. Partial matches down
to three features were used to get the fitness measures of
the active and decoy sets of 1035 compounds. For data fu-
sion one important criteria we used was that we required
all the compounds fitness measures and we screened the
dataset with minimum two features which lead us to get
the scores of compounds which was not listed in three fea-
ture scoring.
Using a python script we extracted the remaining hits
and ranked according to their descending fitness values.
For vROCS screening compounds containing it relevant
conformers were generated using OMEGA [41] with a
maximum of 1000 conformers for each molecule and
using the parameters mentioned in Bostrom et al. [42].
Figure 2 Shows the different pharmacohores developed by Phase E-pharmacophore.
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structure poses of the active compound VIII. We selected
this compound because we used this compound’s
e-pharmacophore in findmatches. The explanation can be
found in the Results and Discussion section.Data fusion
Three different data fusion algorithms were used to gene-
rate data fusion ranks, namely, sum score, sum rank and
reciprocal rank. None of these methods required any train-
ing set which was mandatory in a VS method. Earlier stu-
dies have reported some other similar methods of fusion
[27,43-46]. In Sum score the relative score of each com-
pound is calculated by dividing by the highest score
attained by any compound in a screening method. The
scores were calculated for each VS system and were then
summed to give a new fused score. Sum rank added the
ranks together retrieved from each VS method and
assigned a new rank based on the combined rank value.
The minimum rank value receives the best rank and the
maximum rank value receives the worst rank [31]. The re-
ciprocal rank [46-48] or the rank position method merged
the results based on the rank positions. The rank positions
were summed using the inverse of the rankings given by
equation below.




where Ci is the rank of the compound i and j is the system
index or the VS protocol used.Assessment of virtual screening methods
There are many metrics for evaluation of a predictive
model such as precision ,recall, accuracy, FP measure. But
all of them were not suitable for early recognition of truepositives in a VS experiment. Each of the measures men-
tioned was used for special purpose for example in a classi-
fication problem [18,19]. To determine performance of the
3D methods used in the study, some important measures
were considered i.e., yield of active compounds, percentage
actives and Goodness of a Hit list (GH scoring) were con-
sidered. Percentage yield of actives was the ratio of actives
found in the hit list to the total number of compounds in
the hit list i.e. given by equation 2.
% yield of actives Yað Þ ¼ TP
TP þ FP  100 ð2Þ
Percent actives is the ratio of actives to the total num-
ber of actives (true postives) in the dataset given by
equation 3.
% Actives ¼ TP
A
 100 ð3Þ
The Güner-Henry score i.e. Goodness of hit (GH
score) [49-51] method consist of computing the sensitiv-
ity (recall) eq 4 and specificity (precision) eq 5 and en-
richment factor. The GH score ranges from 0 and 1
where a value of 1 signifies an ideal model. Eq 6 gives
the representation of GH score.
Sensitivity ¼ TP
TP þ FN ð4Þ
Specificity ¼ TN








TP is the number of true positives returned after
screening the database, TN, is the number of true nega-
tives, FP, is the number of false positives ,FN, is the
number of false negatives and A , is the total number of
actives in the database.
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process one of the metrics used is the enrichment factor
(EF) which is defined as the ratio of the probabilities of
searching an active compound in top X% of the data set
[52] given in eq 7.




Where D is the total number of database compounds.
Despite the early recognition problem the EF has some
problems ignoring complete ranking of the whole dataset
molecules [37,53].A method i.e. superior to random selec-
tion of compounds has EF > 1. To address the problem of
EF as discussed in various reports [38,54] Sheridan et al.
developed an exponential weighted scoring scheme RIE















Where Xi ¼ riN is the relative rank of the ith active
compound and α is the tunning parameter. Changing
the parameter α, one can control the early ranking of
hits. BEDROC values ranges in between [0,1] and can be
defined as the probability that an active is ranked before
a randomly selected compound was exponentially dis-
tributed with parameter α. BEDROC and RIE have a lin-
ear relationship [55].
We calculated the BEDROC value for three VS meth-
ods at α=20.At α=20 implies that 80% of the the final
BEDROC score is based on the first 8% of the ranked
data set.Figure 3 The picture represents the E-pharmacophore generated forVirtual screening and data fusion of database hits
E-pharamcophore, vROCS, and glide SP docking were
performed on Asinex datasets in a step by step process.
To select the best scoring molecules from the database
of Asinex we first screened the database using the
e-pharmacophore matching at least 4 features out of five
present in the Pharmacophore model. A distance match-
ing with tolerance of 2 Å was given during pharmaco-
phore mapping of the database along with a minimum
of 4 sites to match the database entries. Also Excluded
volumes were included in search generated from
e-Pharmacophore. Phase find matches retrieved 5000
molecules from the database screen. For vROCS screening
we used the 5000 molecules as the primary dataset and
screened the dataset using the Glide XP docked pose of
compound VIII. We also carried out Glide SP docking
with the 5000 hits retrieved from phase find matches
search. Docking was carried using the prepared protein
2FUM; the ligands were docked into the ATP binding site
of the protein.
All the 5000 hits were ranked accordingly. For
e-pharmacophore shortlisted hits were ranked in des-
cending order, i.e. the highest fitness compound was
given a best rank. ROCS automatically ranked com-
pounds, based on the Tanimoto combo score. Flexible
Glide SP docking was carried out and the ranking was
done based on the docking energy. Then based on the
scores and rankings sum score method was applied for
ranking the hits. The sum score was selected since it
produced the best results than the other fusion methods.
After ranking and screening, the top 500 compounds
(~10%) of the dataset was used for further evaluation.
500 compounds were further docked using the Flexible
Glide XP docking. The binding poses were visually
inspected for 500 molecules. The poses were compared
with the pharmacophore alignment and the moleculesMitoxantrone.
Table 1 The table shows the enrichment factors, BEDROC value and RIE of the different methods applied in virtual
screening
Method EF (1%) EF (2%) EF (5%) EF (10%) BEDROC (α=20) RIE
E-pharmacophore I(5 sites) 12 11 10.51 6.8 0.538 7.81
E-pharmacophore II(7 sites) 30 30 13 6.8 0.729 10.6
E-pharmacophore III(5 sites) 30 27 13 6.5 0.706 10.26
ROCS 30 27 13.14 7.42 0.749 10.89
Glide XP 27 21 11.42 6.28 0.629 9.14
Sum score 30 29 14.85 7.42 0.785 11.42
Sum rank 30 24 12 7.42 0.703 10.21
Reciprocal rank 30 30 17.14 8.85 0.875 12.73
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molecules with a maximum of at least 2 H-bonds with
the hinge region at the ATP binding site were consid-
ered along with any one of the rings.Results and discussion
E-pharmacophore generation
Four e-pharmacophore models were generated using the
six default features for Mitoxantrone (Mtz) and along with
the top 2 docked compounds at the binding site. Though
the methodology of e-Pharmacophore was based on the
concept of structure based pharmacophore, the favorable
pharmacophore sites generated from crystallized com-
pound structure of Mtz were not able to retrieve much ac-
tive compounds with high fitness scores. Figure 3 gives the
view of e-pharmacophore of Mtz. Another most important
aspect to consider was that kinases have specific type of
pharmacophores as described by Zuccotto et al. [56] and
e-pharmacophore of Mtz did not seem to correspond to
any class of kinase pharmacophore. Kinase groups of drugs
are mostly being classified into three types of pharmaco-
phores type I, type II and type I½. Drugs such as sunitinb,
erlotinib and dasatinib fall into the class I type of
Inhibitors. It is found that type I inhibitors are ATP com-
petitive and bind at the ATP site hinge region using one
hydrogen bond acceptor, two hydrogen bond donors and a
hydrophobic moiety [56]. We decided to dock the active
set of 62 compounds to ATP binding site using Glide XP.
After XP docking Compound I gave the best score of
−10.766. Using this compound we generated the
e-pharmacohore I with one acceptor, one donor and three
rings as given in Figure 2. The pharmacophore almost
resembled the type I of inhibitor except without one extraTable 2 Shows the % yield of actives (Ya), %actives, sensitivit
Pharmacophore %Yield Of Actives %Actives
E- pharmacophore I 7 68
E- pharmacophore II 6 74.2
E- pharmacophore III 14.3 65.7donor. The e-pharmacophores gave a score of −2.14 to the
donor site D5 to Val95,-2.10 to the acceptor site A1 also
binding to Val95.The other three were ring aromatics which
are required for the hydrophobic interaction within the
pocket.R10 showed a score of −1.05,R9 with −0.94 and R8
with −0.89. We also found another compound VIII with
low inhibitory concentration (IC50) of 0.039μM on the sec-
ond position of the docked poses. We used compound VIII
to generate another set of e-pharmacophore II it which is
shown in Figure 2.One Acceptor A4 of score −2.08 making
interaction with Val95.Three donors namely D5 having
score of −1.69 and other D6 and D8 having a score of
−0.58 each. Three aromatic rings, R11 having a score of
−0.65 and others R12 and R13 having a score of −0.67 each.
Since seven sites were considered too many for a pharma-
cophore we removed R13 and D8 based on the must match
option for this positions. For must match we used these
two positions R13 and D8 along with any one site from
other remaining 5 sites (D5, D6,A4,R11,R12). The average
enrichment scores for 1%, 2% and 5% of the database com-
pounds was 12.6, 8.96 and 4.42 respectively which was very
low compared to the other pharmacophores I and III. Re-
moving these two sites we found the pharmacophore
resembled the typical class I type pharmacophore [57]. Our
results also showed that most of the active compounds in
our dataset belong to this pharmacophore type with fitness
more than two. Other than that we also calculated the
BEDROC score, RIE, Enrichment scores and AUC using
the R package enrichVS (http://cran.r-project.org/web/
packages/enrichvs/index.html).
E pharmacophore validation
In a VS process when a model gets developed its need to
be also validated. For the three pharmacophores 1000y, specificity and GH score of pharmacophores




Table 3 Shows donor D8 and Ring R13 along with any other pharmcophoric point from 5 sites
Pharmacophore points BEDROC(α=20) RIE %Yield Of Actives %Actives Specificity Goodness of Hit (GH Score)
D8,R12,R13 0.331 4.81 7.3 51.4 0.774 0.1418355
D8,R13,R11 0.306 4.45 11.11 31.4 0.912 0.1475844
D8,R13,A4 0.183 2.67 5.8 14.2 0.919 0.072601
D8,R13,D5 0.32 4.74 11.8 31.4 0.918 0.153306
D8,D6,R13 0.18 2.72 23.8 14.2 0.984 0.210576
This indicates that D8 and R13 cannot be selected as a pharmacophoric point.
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out that whether pharmacophores can find actives and
rank them early. Phase findmatches was applied for each
set of pharmacophores. For E- Pharmacohore I, II and
III a minimum of 4 features out of 5 were given for
search in the database. The enrichments calculated by
the three pharmacophores are given in Table 1. It was
found that for pharmacophore I the enrichments and
the BEDROC value was quite low for other two pharma-
cophores. Also the yield of actives and the goodness of
hit were comparatively low as given in Table 2. It was
observed for pharmacophore II and III that enrichments
scores were quite equal along with percentage yield of
actives, specificity and goodness of hit was quite high
which indicated that the pharmacophore was able to se-
lect active proportion of compounds from the database.
We had derived pharmacophore III from II by removing
the features D8 and R13 from pharmacophore II con-
taining one donor, one ring aromatic. Table 3 gives the
metrics for the donor D8, ring R13 and any one site
from the 5 points. It showed that both D8 and R13 sites
had a very low score of retrieving ranked actives, low %
of yield of actives along with GH score.
The Table 3 indicates that the two point’s donor D8
and ring R13 cannot be selected as pharmacophoric
point for further VS. This was the basis for our selection
of pharmacophore III. Pharmacophore I retrieved hits
well above 0.1 μM but it was observed that when anFigure 4 a) shows the compound VII docked pose at the binding site
mapped to the e-pharmacophore.extra donor D6 is present in the pharmacophore for
example in pharmacophore III activity values decreased
sharply below 0.1μM. Pharmacophore I had a very low
BEDROC, RIE and enrichment for 1%, 2% and 5% of
database hits other than two pharmacophores which
means that this pharmacohore was unable to retrieve
satisfactory highly ranked hits compared to other two
pharmacophores. Figure 4a shows the pharmacophoric
sites and the docking pose of compound VIII at the
active site of Mycobacterium tuberculosis PknB and
Figure 4b shows the active compounds mapped to e-
pharmacophore III.
Shape based screening
For shape based screening we used the same 1035 data-
set used for pharmacophore validation i.e. 1000 decoys
and 35 active molecules. For query the docked pose of
compound VIII was taken. After screening the max-
imum value of the Tanimoto Combo score attained was
1.418. The roc area obtained by vROCS program was
0.89 which was higher than the pharmacophore search
and docking.Glide XP docking
To check the enrichment of the structure based
approaches such as docking, we also tested the compounds
with Glide XP mode of docking. It approximately took
around 72 hrs. to dock 1035 compounds. The roc areawith e-pharmacophore sites. b) shows the actives compounds
Table 4 It shows the ROC AUC’s of VS methods and data
fusion
Methods AUC(1%) AUC(2%) AUC(5%) AUC(100%)
E-pharmacophore III 0.56 0.602 0.649 0.832
ROCS 0.58 0.62 0.62 0.89
Glide XP 0.39 0.44 0.51 0.84
Sum score 0.64 0.6780 0.717 0.90
Sum rank 0.47 0.49 0.565 0.91
Reciprocal rank 0.72 0.75 0.81 0.96
Figure 5 a) It shows the enrichment plots for VS methods and b) shows the enrichment plots for data fusion.
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ment plot of e- pharmacophore III, ROCS and Glide XP
docking for all the 1035 database molecules.
Data fusion
Several data fusion algorithms have been successfully
implemented and it has been found that the algorithms
scores and ranks compound much better than a single
VS method. In this work we have implemented three
very simple fusion methods namely sum score, sum rank
and reciprocal rank. The study and statistics showed that
reciprocal rank performed better among all the other
methods with the highest BEDROC score and RIE score
followed by Sum score. Both of these algorithms were
able to retrieve highly ranked hits. Table 4 shows the
area under the roc curve values for VS methods and
data fusion. It shows reciprocal rank can retrieve hits
much better in 1%, 2%, 5% and 100% of the database.
Virtual screening of Asinex database
With e-pharmacophore III giving the best possible BED-
ROC and RIE score among the other pharmacophore
models, we selected this pharmacophore model for our
prepared virtual database of Asinex. We selected top
5000 hits for our work in which only 222 hits scored
above 2.0 other than that it was very interesting among
all the 222 hits, there were only 14 compounds which
met all the necessary five sites of the pharmacophore.
Most of the compounds in top 222 lacked the D6 donor
site of pharmacophore III. But in the active set we found
that there were some compounds which lacked this site
showed a good docking score with one acceptor and one
donor. For shape based screening of 5000 compounds a
maximum of 1000 conformers per molecule were gene-
rated using the parameters set by Bostrom et al. [42].
Then we ran vROCS using the Glide XP docked query
for the generated dataset. For vROCS query themaximum Tanimoto combo score attained after screen-
ing was 1.19. Ranking of the vROCS results was done by
the program itself. Due to time and power limitations
we used Glide SP for docking purpose. All the 5000
molecules were ranked in ascending order of the dock-
ing score. For data fusion we used reciprocal rank algo-
rithm to rank the compounds as because it performed
the best among all the other fusion algorithms. After
ranking was done top 10% (500 compounds) of the data-
base hits ranked by reciprocal rank were docked in the
2FUM ATP binding site with Glide XP docking algo-
rithm. Then each of the 500 poses were visually
inspected and mapped to the pharmacophoric sites. We
selected a list of 45 inhibitors which matched the above
limitations and also resembling the pose of compound
VIII. Additional file 3 contains the structures of 45
compounds.
Physicochemical space of the PknB inhibitors
It is well known that the antibacterial drugs covers a
wide range of chemical space [58]. Antibacterials does
not follow Lipinski’s rules as they have high polar sur-
face area, low lipophilicity and high molecular weights
[57,59]. We studied 12 different physicochemical prop-
erties including molecular refractivity, atom polarizabil-
ities, bond polarizabilities, hydrogen bond donors and
Figure 6 It shows the Principal component analysis study of the PknB inhibitors and our predicted compounds. The numbers of the
compounds assigned as the positions in the sdf format of Additional file 3.
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http://www.jcheminf.com/content/5/1/2acceptors, petitjean number, topological polar surface
area, number of rotatable bonds, liphophilicity XLogP,
molecular weight, topological shape and geometrical
shape. The twelve properties were calculated using
Chemistry development kit tool developed by Guha
(http://rguha.net/code/java/cdkdesc.html) [60]. A prin-
cipal component analysis (PCA) was done using the 12
chemical properties which transform a set of correlated
variables into a number of uncorrelated variables called
principal components was done using R princomp func-
tion. Principal component 1 and 2 is plotted in the x
and y axis which has the maximum variance is shown in
Figure 6. The x and y axes are linear combinations of
the 12 properties and each data point in the two dimen-
sional graph corresponds to one compound. It has been
found that the PknB inhibitors have a wide distribution
of in chemical space. It was found that many different
set of compounds which were structurally different
appeared in different wide positions in chemical space.Figure 7 Showing some of the top ranked selected hits binding to thSome of the compounds are labeled in Figure 6. Our
predicted 58 group of compounds fall into the section
of the active set of PknB inhibitors which means that
these compounds share similar physicochemical proper-
ties with the PknB inhibitors. A set of some predicted
compounds binding to the active ATP site of PknB is
given in Figure 7.
Conclusion
In this work we have created the Mycobacterium
tuberculosis PknB pharmacophore model which is can
be used for further development high affinity com-
pounds. We have developed three pharmacophore mod-
els using e-pharmacophore and came to find out that
most of the active compounds in the dataset of 62 com-
pounds resemble the kinase type I pharmacophore [54]
which is represented by e-pharmacophore III. Data fu-
sion methods previously being implemented in 2D
screening protocols [27] and also now being widelye PknB active site.
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http://www.jcheminf.com/content/5/1/2accepted in 3D screening methods. In our work we have
used sum score, sum rank and reciprocal rank algorithms.
Reciprocal rank algorithm is used in the information re-
trieval systems in meta search engines [47]. It has been
found that previously no one has implemented the recipro-
cal rank algorithm for data fusion using 3D methods. We
have found that reciprocal rank algorithm performed bet-
ter than sum score and sum rank fusion methods results
which indicates that it can rank molecules better in a VS
run. After running a virtual screening run we have found
identified compounds based on reciprocal rank algorithm
and further docking by glide XP and pharmacophore map-
ping. We did found around 45 compounds which were
having one acceptor and one donor and one ring. We also
mapped the compounds to the physicochemical space of
the PknB inhibitors and found that many of the com-
pounds fall in the same physicochemical region as of PknB
inhibitors. The set of 45 compounds in the Additional file
3 could be further processed for experimental validation
against PknB.Experimental
Datasets
The following are the datasets used for these experiments.
Additional file 1: The PknB dataset of 62 inhibitors
which contains Pubmed ID and IC50 values of inhibitors.
Additional file 2: The validation dataset of 1035 com-
pounds in which 35 are active compounds and 1000 are
decoys.
Additional file 3: It contains 45 compounds which are
visually mapped with pharmacophore and Glide XP
docking. It also contains the reciprocal rank scores of
the compounds along with the Glide XP docking scores,
Tanimoto Combo Score and pharmacophore fitness
values.
Additional files
Additional file 1: The PknB dataset of 62 inhibitors which contains
Pubmed ID and IC50 values of inhibitors.
Additional file 2: The validation dataset of 1035 compounds in
which 35 are active compounds and 1000 are decoys.
Additional file 3: It contains 45 compounds which are visually
mapped with pharmacophore and Glide XP docking. It also contains
the reciprocal rank scores of the compounds along with the Glide XP
docking scores, Tanimoto Combo Score and pharmacophore fitness
values.
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